Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOX versus S-1 in gemcitabine-refractory pancreatic cancer
jRCT2080220660Phase 3
- Sponsor
- Yakult Honsha
- Start
- Jan 2009
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in pancreatic adenocarcinoma (PDAC), pancreatic adenosquamous carcinoma (PASC) and pancreatic cancer (PC) comparing SOX (oxaliplatin + S-1) with S-1 monotherapy (2 arms).
02
Drugs
oxaliplatintegafur
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic adenosquamous carcinoma (PASC)pancreatic cancer (PC)
Beyond the preview
Go deeper on jRCT2080220660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220660.